NasdaqGS:ACRSPharmaceuticals
Aclaris Therapeutics (ACRS) Quarterly Loss Near US$20 Million Reinforces Bearish Earnings Narrative
Aclaris Therapeutics (ACRS) opened Q1 2026 with revenue of about US$2.0 million and a basic EPS loss of roughly US$0.15 per share. Trailing twelve month figures show revenue of US$8.4 million and a cumulative basic EPS loss of around US$0.56. Over recent quarters, revenue has moved between US$1.3 million and US$3.3 million, while quarterly basic EPS losses have sat in a range of roughly US$0.12 to US$0.16 per share, keeping the focus squarely on how much further margins can be tightened to...